10/30/2026
As of Friday, October 30th, Ambros Therapeutics' neridronate trial now has 33 sites.
Visit crps-rise.com for more details as well as their study page on the ClinicalTrials.gov website (https://bit.ly/4u7YSfa) as new trial sites are rolling out weekly!
This is *not* CRPSA's study. Please direct study questions and comments to [email protected].
Learn more about neridronate via Dr. Stephen Bruehl from our 2025 conference: https://bit.ly/3TFTbJ1
→ Phoenix, AZ
→ Tucson, AZ
→ Little Rock, AR
→ La Jolla, CA
→ Napa, CA
→ Pasadena, CA
→ Santa Monica, CA
→ Tustin, CA
→ Washington, DC
→ Brandon, FL
→ Daytona Beach, FL
→ Pembroke Pines, FL
→ Lawrenceville, GA
→ Newnan, GA
→ Chicago, IL (new)
→ Orland Park, IL
→ Overland Park, KS
→ Dearborn, MI (new)
→ Reno, NV
→ Shrewsbury, NJ
→ Charlotte, NC
→ Wilmington, NC
→ Winston-Salem, NC
→ Cleveland, OH
→ Dayton, OH
→ Fort Worth, Texas
→ Houston, TX
→ Lubbock, TX
→ Mesquite, TX
→ Charlottesville, VA
→ Richmond, VA
→ Seattle, WA